Loading clinical trials...
Loading clinical trials...
The purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of PE in pregnancy in women with primary APS. To construct reference intervals of placental angiogenesis markers specific to women affected by primary APS in pregnancy by measuring the levels of sFlt-1and PlGF in serum maternal serum and their sFlt-1/PlGF ratio during the trimesters of gestation (I TM, II TM and III TM). For this aim the study will involve recruiting two groups of subjects, one will be cases and one will be controls.
Age
18 - 45 years
Sex
FEMALE
Healthy Volunteers
Yes
San Raffaele Hospital
Milan, Italy
Start Date
December 6, 2022
Primary Completion Date
December 6, 2025
Completion Date
June 6, 2026
Last Updated
June 18, 2025
60
ESTIMATED participants
Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
OTHER
Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
OTHER
Lead Sponsor
IRCCS San Raffaele
NCT07485140
NCT06749418
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05999851